These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
391 related articles for article (PubMed ID: 24276642)
1. Melphalan: a promising agent in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Sardi A; Jimenez W; Nieroda C; Sittig M; Shankar S; Gushchin V Ann Surg Oncol; 2014 Mar; 21(3):908-14. PubMed ID: 24276642 [TBL] [Abstract][Full Text] [Related]
2. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes. Sardi A; Jimenez WA; Nieroda C; Sittig M; Macdonald R; Gushchin V Eur J Surg Oncol; 2013 Nov; 39(11):1207-13. PubMed ID: 24007834 [TBL] [Abstract][Full Text] [Related]
3. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239 [TBL] [Abstract][Full Text] [Related]
4. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis. Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149 [TBL] [Abstract][Full Text] [Related]
5. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504 [TBL] [Abstract][Full Text] [Related]
6. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis. El Halabi H; Gushchin V; Francis J; Athas N; Macdonald R; Nieroda C; Studeman K; Sardi A Ann Surg Oncol; 2012 Jan; 19(1):110-4. PubMed ID: 21701929 [TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Survival in Patients with Isolated Peritoneal Carcinomatosis from Colorectal Cancer Treated with Cytoreduction and Melphalan or Mitomycin-C as Hyperthermic Intraperitoneal Chemotherapy Agent. Sipok A; Sardi A; Nieroda C; King MC; Sittig M; Gushchin V Int J Surg Oncol; 2018; 2018():1920276. PubMed ID: 30643644 [TBL] [Abstract][Full Text] [Related]
9. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution. Teo MC; Tan GH; Tham CK; Lim C; Soo KC Ann Surg Oncol; 2013 Sep; 20(9):2968-74. PubMed ID: 23504144 [TBL] [Abstract][Full Text] [Related]
10. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center. Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715 [TBL] [Abstract][Full Text] [Related]
11. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304 [TBL] [Abstract][Full Text] [Related]
12. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis. Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884 [TBL] [Abstract][Full Text] [Related]
13. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis. Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744 [TBL] [Abstract][Full Text] [Related]
14. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with peritoneal hepatocellular carcinoma. Tabrizian P; Franssen B; Jibara G; Sweeney R; Sarpel U; Schwartz M; Labow D J Surg Oncol; 2014 Dec; 110(7):786-90. PubMed ID: 25091997 [TBL] [Abstract][Full Text] [Related]
15. Treatment of ovarian metastases of colorectal and appendiceal carcinoma in the era of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Kuijpers AM; Mehta AM; Aalbers AG; van Driel WJ; Boot H; Verwaal VJ Eur J Surg Oncol; 2014 Aug; 40(8):937-42. PubMed ID: 24630923 [TBL] [Abstract][Full Text] [Related]
16. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study. Hompes D; D'Hoore A; Van Cutsem E; Fieuws S; Ceelen W; Peeters M; Van der Speeten K; Bertrand C; Legendre H; Kerger J Ann Surg Oncol; 2012 Jul; 19(7):2186-94. PubMed ID: 22395983 [TBL] [Abstract][Full Text] [Related]
17. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129 [TBL] [Abstract][Full Text] [Related]
18. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. Canbay E; Mizumoto A; Ichinose M; Ishibashi H; Sako S; Hirano M; Takao N; Yonemura Y Ann Surg Oncol; 2014 Apr; 21(4):1147-52. PubMed ID: 24356799 [TBL] [Abstract][Full Text] [Related]
19. Cytoreduction and hyperthermic intraperitoneal chemotherapy: a feasible and effective option for colorectal cancer patients after emergency surgery in the presence of peritoneal carcinomatosis. van Oudheusden TR; Braam HJ; Nienhuijs SW; Wiezer MJ; van Ramshorst B; Luyer MD; Lemmens VE; de Hingh IH Ann Surg Oncol; 2014 Aug; 21(8):2621-6. PubMed ID: 24671638 [TBL] [Abstract][Full Text] [Related]
20. Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis. Marcotte E; Dubé P; Drolet P; Mitchell A; Frenette S; Leblanc G; Leclerc YE; Sideris L World J Surg Oncol; 2014 Nov; 12():332. PubMed ID: 25380618 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]